Affiliation:
1. Division of Gastroenterology, Zigong First People’s Hospital, 42 Shangyihao Road, Zigong-643000, Sichuan, China
Abstract
Background:
Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is a severe
complication with a poor prognosis. Recently, mesenchymal stem cell (MSC)-based therapy for HBVACLF
has shown considerable promise. Therefore, this systematic review and meta-analysis aimed to
evaluate the efficacy and safety of MSC transplantation for patients with HBV-ACLF.
Methods:
The PubMed, Cochrane Library, CNKI, and Embase databases were searched from their inception
to March 2021 for reports on MSC therapy for HBV-ACLF. We used RevMan 5.3 to perform the
systematic review and meta-analysis.
Results:
Four studies were ultimately included. Compared with the control treatment, allogeneic MSC
treatment resulted in a higher cumulative survival rate among ACLF patients (OR=2.27; 95% CI 1.35,
3.81; p=0.002). The umbilical cord-derived MSC (UC-MSC) group obtained a higher survival rate than
the control group (OR = 2.33; 95% CI 1.17, 4.63; p=0.02). The group with multiple interval peripheral
vein injections of MSCs obtained a higher survival rate than the control group (OR = 2.09; 95% CI 1.20,
3.67; p=0.01). None of the adverse events were MSC-related.
Conclusion:
Our study indicates that MSC transplantation can significantly increase survival rates by
improving liver function without severe adverse events. UC-MSCs harvested for allogeneic infusion via
peripheral veins appear to provide superior treatment for patients.
Publisher
Bentham Science Publishers Ltd.
Subject
General Medicine,Medicine (miscellaneous)
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献